Project Grant W81XWH1810569

The Massachusetts General Hospital will repurpose the drug phenformin to develop treatments for NF1-mutant malignant peripheral nerve sheath tumors (MPNST) under a $161,150 Project Grant from the Department of the Army Medical Command. The grant is part of the Military Medical Research and Development program administered by the agency under Catalog of Federal Domestic Assistance number 12.420. This program supports biomedical research that transforms military and public health, including...

The University of Texas MD Anderson Cancer Center received a $1,431,215 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop T-cell products for the treatment of NF1-associated malignant peripheral nerve sheath tumors (MPNST). The project aims to discover new antigens and leverage epigenome targeting to engineer improved T-cell therapies for this rare and aggressive cancer. The award commenced on October 1, 2025, with a...

The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $451,000 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to The Regents of the University of California, San Francisco (UCSF) to develop and characterize metastatic MYB-NFIB fusion adenoid cystic carcinoma (ACC) cell line models. The goal is to better understand the oncogenic function of these gene fusions and identify potential drug targets, as ACC is a rare but deadly salivary...

The University of Chicago was awarded a $230,010 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to conduct research on uncovering the cellular and molecular drivers behind the aggressive metastatic potential of small cell lung cancer (SCLC). The project aims to leverage innovative human pluripotent stem cell-derived models of SCLC to gain deeper insights into this complex issue. By examining cell behavior in both primary tumors and...

This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...

The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $931,113 project grant to The University of Texas MD Anderson Cancer Center, with a performance period from November 1, 2024 to October 31, 2027. The grant supports research targeting RNA surveillance machinery in neurofibromatosis type 1 (NF1)-mutant malignant peripheral nerve sheath tumors (MPNSTs). As a leading academic cancer research institution, MD Anderson has extensive expertise...

This federal Project Grant award of $417,858 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System) is funding the development of novel engineered mesenchymal stem cell (MSC) therapies that release bi-specific T cell engagers (BiTEs) to target brain tumors called glioblastomas (GBMs). The key products and services to be delivered under this 5-year grant include: 1) Engineering MSCs to...

The federal Project Grant award R01CA289387, totaling $657,121.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports research conducted by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida to develop a novel dendritic cell therapy for treating leptomeningeal disease (LMD), a severe complication that occurs in 5% of advanced-stage breast cancer patients. The research aims to...

This federal Project Grant award of $513,127 from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) supports research by The University of Texas MD Anderson Cancer Center to investigate the role of cancer pain-associated neuronal activity in driving malignancies. The researchers aim to uncover how malignant peripheral nerve sheath tumor (MPNST) cells activate sensory neurons to promote cancer pain, and determine the mechanisms by which pain-associated...

The National Institute of Neurological Disorders and Stroke (NINDS) has awarded a $1,151,209 Project Grant to The Leland Stanford Junior University (Stanford University) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant will support research to investigate a novel molecular driver of schwannoma nerve sheath tumors. The project aims to study recurrent in-frame insertions or deletions in the SOX10 gene, which encodes a...